The latest announcement is out from Kuros Biosciences ( (CH:KURN) ).
Kuros Biosciences reported an 82% year-over-year increase in sales for the first quarter of 2025, with total medical device sales reaching USD 28.8 million. The company achieved a significant milestone with monthly revenues surpassing USD 10 million for the first time. Kuros is proactively expanding its global footprint, with MagnetOs products gaining commercial clearance in Brazil and Lebanon, and is taking strategic steps to mitigate potential impacts from upcoming U.S. tariffs by increasing inventory and diversifying production. Recent clinical studies have demonstrated high fusion rates for MagnetOs in high-risk patients, further validating its efficacy and supporting the company’s growth momentum.
More about Kuros Biosciences
Kuros Biosciences is a company focused on discovering, developing, and delivering innovative biologic technologies. With operations in the United States, Switzerland, and the Netherlands, it is listed on the SIX Swiss Exchange. Its flagship product, MagnetOs, is an advanced bone graft used across four continents.
YTD Price Performance: -15.15%
Average Trading Volume: 968
Technical Sentiment Signal: Sell
Current Market Cap: $772.7M
See more insights into KURN stock on TipRanks’ Stock Analysis page.